Protocol Ledger

NCT06643481 · Phase II · ACTIVE NOT RECRUITING

A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS)

Interventional Phase II clinical trial protocol NCT06643481 sponsored by Novartis in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-10-17 Enrollment: 251 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06643481
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)251 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06643481
Protocol FieldVerified Registry Value
NCT IdentifierNCT06643481
Consolidated Lead SponsorNovartis
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment251 participants (ACTUAL)
Registered Start Date2024-10-17
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Novartis across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI